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This research was aimed to evaluate the in vitro antiviral effect and the mechanism of the effect of
Peganum. harmala seeds extract against inﬂuenza A virus infection using Madin-Darby canine kidney
(MDCK) cells. In this research, ethyl alcohol extract of P. harmala seeds and its total alkaloids was pre-
pared. The potential antiviral activity of the extract and its total alkaloids against inﬂuenza A/Puerto Rico/
8/34 (H1N1; PR8) virus was assessed. The mode of action of the extract to inhibit inﬂuenza replication
was investigated using virucidal activity, hemagglutination inhibition assay, time of addition assays, RNA
replication, western blot analysis and RNA polymerase blocking assay. The crud extract of P. harmala seed
and its total alkaloids showed the best inhibitory effect against inﬂuenza A virus replication in MDCK
cells using MTT assay, TCID50 method and hemagglutination assay. Our results indicated that the extract
inhibits viral RNA replication and viral polymerase activity but did not effect on hemagglutination in-
hibition and virucidal activity. This study showed that, in vitro antiviral activity of P. harmala seed extract
against inﬂuenza virus is most probably associated with inhibiting viral RNA transcription. Therefore, this
extract and its total alkaloid should be further characterized to be developed as anti-inﬂuenza A virus
agent.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Inﬂuenza is an acute respiratory infection caused by inﬂuenza
viruses, which circulate through all parts of the world. Hospitali-
zation and death occur mainly between high-risk groups. World-
wide, the annual epidemics are estimated to result in about 3e5
million cases of severe illness, and about 250 000 to 500 000 deaths
[1]. Pandemic yields different mortality estimates. Segmented
ribonucleic acid genome and animal reservoir cause genetic reas-
sortment in the virus. The appearance of new human and non-
human source of inﬂuenza virus with the ability to cross-species
barriers creates with high rate of antigenic drift and shift; also it
changes to pathogenic type in their new hosts [2,3].
Annual vaccination is the mainstay strategy for preventing
inﬂuenza infections and antiviral drugs offer additional preventive
and therapeutic beneﬁts [4]. In order to treat anti-inﬂuenza A virusi).two main groups of medicines including matrix protein (M2), ion-
channel inhibitors (Amantadine and Rimantadine), and neur-
aminidase inhibitors (Oseltamivir, Zanamivir, and Peramivir) are
conﬁrmed [5]. The neuraminidase inhibitors are widely used in the
treatment of both seasonal and pandemic inﬂuenza virus in-
fections. However, oseltamivir resistant H1N1 strains were found to
be circulated since the 2007e2008 [6,7]. As, the constant evolve-
ment of inﬂuenza A virus causes the rapid emergence of resistance
to current medicines [8e10], Therefore, it is essential to make the
new and efﬁcient anti-inﬂuenza medicines in order to treat resis-
tant forms of inﬂuenza A virus.
Use of herbal extracts seems to be an alternative. There are some
medicinal plants containing active compounds which have been
used as remedies and as sources of herbal medicines. Many
screening experiments have been carried out to isolate the extracts
with antiviral activity from these plants [11e13]. Some of these
herbal medicines have been developed into therapeutic agents and
have had promising results.
Peganum harmala L. (family Zygophyllaceae) is a perennial,
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rica, India, South America, southern America, China and most areas
of Iran [14]. Seed, fruit, root, and bark of this plant have been used,
as folk medicine, for a long time in Iran, Turkey, and China to treat
coughs, rheumatism, hypertension, diabetes and asthma [15e17].
Phytochemical compounds from P. harmala are alkaloids, ﬂa-
vonoids, amino acids, polysaccharides and anthraquinones [18].
The pharmacologically active compounds of P. harmala are several
alkaloids, which are found especially in the seeds and the roots.
These include b-carbolines such as: harmine, harmaline, harmalol
and harman and quinazoline derivatives: vasicine and vasicinone
[14].
Literature survey revealed that P. harmala and its active alkaloids
possess a wide range of pharmacological activities [16,17]. Several
studies have revealed anti parasitic [19,20], antifungal, antibacterial
[21], insecticidal [22,23] and antiviral [24,25] effects from
P. harmala and its alkaloids.
This research, most probably as a ﬁrst work of this kind, was
aimed to evaluate in vitro anti-viral activity of seed extract of
P. harmala L. against inﬂuenza A virus infection.
2. Methods and materials
2.1. Plant collection, crude extract and total alkaloid extraction
Seeds of Peganum harmala were purchased from a reliable
drugstore. Then, in the Herbarium of Medical Plants Research
Center of the Shahrekord University of Medical Sciences (Iran),
genus and species of the plant were identiﬁed and conﬁrmed. The
seeds were powdered and then extracted using maceration
method. The plant material was dissolved in 80% ethyl alcohol and
kept at room temperature for 96 h then, the mixture was ﬁltered
and concentrated under nearly vacuum pressure and at 40 C using
rotary evaporator.
Total alkaloids were extracted from the ethanol extract as
described previously [26]. Brieﬂy, the crude extract was ﬁrst
defatted by using n-Hexan to remove all fat soluble (liposoluble)
ingredients and fatty oil. The ethanol extract was subsequently
dissolved in 5%HCl (to get pH¼ 5) and ﬁltered. The ﬁltrate was then
partitioned three times with ethyl acetate and the aqueous acid
layer was combined and dried under reduced pressure to give total
alkaloid.
2.2. Cell culture and inﬂuenza virus propagation
Madin Darby Canine Kidney (MDCK) cell line and Inﬂuenza virus
A/Puerto Rico/8/34 (H1N1; PR8), was obtained from Inﬂuenza Unit,
Pasteur Institute of Iran. MDCK cells were grown in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) (Gibco, USA), supplemented
with 10% Fetal Bovine Serum (FBS) (Gibco, USA) and 1% Pen/Strep
(Gibco, USA) at 37 C in a 5% CO2 atmosphere and humidiﬁed
incubator.
2.3. Cytotoxic assay
The effect of crude extract and total Alkaloids of P. harmala on
the viability of MDCK cells were determined by 3-[4,5-dimethyl
thiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay
(Sigma, USA) as described previously [27] with somemodiﬁcations.
Brieﬂy, when the cell monolayer was conﬂuent, the cells were
incubated with 200 mL/well of various concentrations of the
extract/fractions (in triplicates) in 96 well plates for further 2 days.
Then cell monolayers were incubatedwith 50 mL of 1mg/mLMTT in
PBS at 37 C for 4 h, then treated with 100 mL of isopropanol with
HCl. After shaking the plates for 15 min, the absorbance was read at570 nm with a reference ﬁlter at 640 nm using an enzyme-linked
immunosorbent assay (ELISA) reader (StatFax 2100, USA).
2.4. Cytopathic effect (CPE) reduction assay
Conﬂuent MDCK cells monolayer in 96 well plates were infected
with 100 ml (100TCID50) inﬂuenza A (H1N1) virus and incubated at
37 C for about 1 h to allow virus adsorption. Then, the virus was
removed and the cells were treated with serial two-fold dilutions of
nontoxic concentration of the extract or total alkaloid (200 ml/well)
in serum-free DMEM containing 2 mg/ml TPCK-trypsin and 0.3%
BSA. On 48 h post infection cell viability was also determined using
previously described MTT assay [27]. A solution of oseltamivir
(Sigma, USA) were used as positive controls. The procedure was
carried out in triplicate.
The 50% cytotoxic concentration (CC50) and 50% inhibitory
concentration (IC50) were calculated using regression analysis and
related models with probit regression model procedure, using the
SPSS software (version 16.0). Selectivity index (SI) was calculated as
ratio of CC50 to IC50.
2.5. Hemagglutination (HA) assay
ConﬂuentMDCK cells monolayer in 24-well plateswere infected
with PR8 virus (100TCID50), inoculated with virus at 1 h at 37 C
and cultured in DMEM and TPCK trypsin (0.5 mg/ml; Sigma, USA)
either with or without extract/alkaloid treatment. The cell culture
supernatants were harvested at 24 and 48 h post infection. Fifty
microliters of the two fold serial dilutions of the cell culture su-
pernatants were mixed with the same volume of 0.5% chicken red
blood cells (RBCs) in U-bottomed 96-well plate for 45 min at room
temperature. The HA assay activity was determined by measuring
the dilution factor of the samples required for complete HA assay
mediated chicken RBC agglutination [28].
2.6. TCID50 virus titration
ConﬂuentMDCK cells monolayer in 24-well plateswere infected
with PR8 virus (100TCID50) in the presence of the extract/alkaloid
or control compounds for 24 h at 37 C. A standard 50% tissue
culture infectious doses (TCID50) method was used for virus titra-
tion in culture supernatants [29]. Brieﬂy, when 90% conﬂuent,
MDCK cells were prepared in 96 well plates, the cell culture me-
dium was aspirated and washed twice with phosphate-buffered
saline (PBS) then 100 ml of a series of 10-fold dilutions was added
into the wells and left to incubate for 2 days. After 48 h, 50 ml of
culture mediumwere taken from each well and transferred to a U-
bottomed 96-well plate for HA assay [30]. TCID50 was calculated
based on the Reed and Muench method [31].
2.7. Quantitative reverse transcription-PCR
We used real time PCR to quantify the presence of virus in the
media after infection with inﬂuenza virus. Conﬂuent MDCK cells
monolayer in 12-well plates were infected with PR8 virus
(100TCID50) in the presence of the extract/alkaloid or control
compounds for 24 h at 37 C. Inﬂuenza viral RNA was extracted
from the culture supernatant with a viral nucleic acid extraction kit
(Yekta tajhiz azma Co., Iran), and reverse transcribed to cDNA using
RevertAid First Strand cDNA synthesis kit (Thermo scientiﬁc,
Lithuania) and an inﬂuenza A viral RNA-speciﬁc universal Uni12
primer (50-AGCAAAAGCAGG-30). Quantitative PCR was performed
using inﬂuenza NS1 gene primer (Table 1) and 2x SYBER Green
Master Mix (Thermo scientiﬁc, Lithuania) with a Rotor-Gene Q
(Corbett, Qiagen, Germany). The viral RNA level from the virus-
Table 1
Primers used in real-time RT-PCR.
Gene name Primer sequence Melt temperature (C) Product length (bp)
Nucleocapsid protein (NP) F:TGTGTATGGACCTGCCGTAGC
R:CCATCCACACCAGTTGACTCTTG
62.1
61.3
158
Hemagglutinin (HA) F:CCTGCTCGAAGACAGCCACAACG
R:TTCCCAAGAGCCATCCGGCGA
60.6
58.3
98
Nonstructural protein (NS1) F:CATAATGGATCCAAACACTGTGTC
R:CCTCTTAGGGATTTCTGATCTCGG
58.1
60
138
Matrix protein (M) F: GGCAAATGGTACAGGCAATG
R: AGCAACGAGAGGATCACTTG
57.7
57.6
144
GAPDH F: GGAGAAAGCTGCCAAATATGACGA
R: CGAAGGTGGAAGAGTGGGTGT
61.4
61.9
140
GAPDH: Canis lupus familiaris glyceraldehyde-3-phosphate dehydrogenase.
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from the test samples were calculated.
2.8. Time-of-addition experiments
To determine the stage of the viral life cycle that is affected by
P. harmala seed extract, MDCK cells were seeded into 24-well plates
and incubated overnight until 90% conﬂuence. After incubated with
virus (104TCID50) for 1 h at 37 C, the cells were washed with PBS,
and then fresh medium containing TPCK and the extract at its
maximum non-toxic concentration (100 mg/ml) was added. The
crude extract was added at the following time points: 2 to 1 h
(before the adsorption of the virus), 1 to 0 h (adsorption) as well
as at three time points post adsorption: 0e2, 2e4, and 4e8 h. The
treatment (2)-8 h post infection was considered as a positive
control. In each case after incubation the extract was removed and
cells were washed and then fresh medium containing TPCK was
added. After 8 h of incubation, supernatants were taken and
progeny virus yields were determined using previously described
TCID50 assay [32,33].
2.9. Virucidal activity
P. harmala seed extract at maximum non-toxic dilution (100 mg/
ml) and PBS was incubated with the virus (104TCID50) for 1 h at
room temperature. Then, the infectious titer of the virus in culture
medium was determined using previously described TCID50 assay
[32].
2.10. Inhibition of viral mRNA expression and viral RNA synthesis
Conﬂuent MDCK cells in 12-well plates were infected with the
virus, and cultured in the presence of P. harmala seed extract
(100 mg/ml) for 13 h [34]. Total RNA was extracted from the MDCK
cells inoculated with either the treated or untreated viruses using
Trizol (Invitrogen, Waltham,MA, USA) according to the manufac-
turer's instructions. The obtained RNA was transcribed into cDNA
by RevertAid First Strand cDNA synthesis kit (Thermo scientiﬁc,
Lithuania) including an inﬂuenza A viral RNA-speciﬁc universal
primer Uni12 (to detect viral RNA) or oligo-dT (for viral mRNA
detection) primers [35], 5X Reaction buffer, RNase inhibitor and
dNTP Mix to a ﬁnal volume of 20 ml. The quantiﬁcation of viral
mRNA (vmRNA) and viral RNA (vRNA) levels was performed using a
Rotor-Gene Q (Corbett, Qiagen, Germany) in a total volume of 10 ml
containing 1 ml of synthesized cDNA solution, 5 ml of 2x SYBER
Green Master Mix (Thermo scientiﬁc, Lithuania) and 500 nM of
each primer (Table 1). Ampliﬁcation program included a denatur-
ation at 95 C for 10min followed by 45 cycles at 95 C for 15 s, 54 or
58 C for 20 s, and 72 C for 25s. Following the ampliﬁcation, the
speciﬁcity of the ampliﬁed products was conﬁrmed using meltingcurve analysis. All the reactions were performed in of 2 indepen-
dent repeats in duplicate and a mixture containing no cDNA tem-
platewas used as the negative control. The expression of mRNAwas
normalized to that of the control housekeeping gene (GAPDH), and
the relative changes in gene expression were calculated using the
relative quantitative method (2DDCt). The effects on viral RNA
synthesis were shown by log10 copy number decrements in
treatments which were calculated through absolute quantiﬁcation.2.11. Construction of the plasmid standards for quantiﬁcation
For quantiﬁcation of real-time PCR assay, the ampliﬁed M2 gene
were T/A cloned in pTZ57 R/T vector (Invitrogen, San Diego, CA).
Vectors were transformed into E. coli TOP10F0 competent cells using
calcium chloride solution and under heat shock (42 C) for 90s. For
screening of recombinant vectors, competent cells were cultured in
Luria broth (LB) agar media (Merck Co., Germany) containing
Ampicillin antibiotic (100 mg/mL), IPTG (0.1 M) and Xgal (20 mg/
mL) at 37 C overnight. The white colonies were selected and
cultured again in LB broth media (containing Ampicillin antibiotic)
at 37 C overnight. The recombinant vectors were extracted from
bacterial cells by PlasmidMini Extraction Kit (Bioneer, South Korea)
using manufacturer's instructions and PCR analysis was used for
conﬁrmation of cloning. The concentration of extracted plasmids
were measured spectrophotometrically using a Nano drop system
(Implen Nano Photometer™, Germany). The plasmids copy number
were calculated taking into account the size of the original plasmid
plus the cloned inserts and the concentration of the construct by
following formula [36]:
Number of copies=ml ¼ ½6:02 1023copies
 plasmid concentrations ðg=mlÞ=
 ½Number of bases pairs
 660 daltons=base
To plot standard curves, ten-fold serial dilutions of the plasmid
(107 copies to 100 copy) were prepared and the M2 gene in plas-
mids were ampliﬁed in three replicates for each standard dilution
point. Real time RT-PCR quantiﬁcation was accomplished using the
method for measuring the expression of the gene.2.12. Hemagglutination inhibition (HI) assay
The hemagglutination inhibition (HI) assay was employed to
test the effect of the extract on inﬂuenza virus hemagglutinin [37].
Brieﬂy, 50 mL of two fold serial dilutions of the extract diluted in PBS
containing 0.1% BSA was mixed with 50 mL of the virus in PBS
containing 0.1% BSA. After 1 h of incubation, the hemagglutination
assay was carried out to measure virus titration. Titers are given as
Fig. 1. Cytotoxicity and anti-inﬂuenza virus activity of crude extract and total alkaloids of Peganum harmala L. Conﬂuent MDCK cells were exposed to different concentrations
of crud extract or total alkaloids for 48 h without virus (A) or after inﬂuenza viruses (PR8) infection (B). Cell viability was measured in MTT test. Results are means ± SD from three
experiments.
Table 2
Hemagglutination titers of PR8-infected MDCK cell supernatants in the presence of
the Peganum harmala L. seed crud extract and total alkaloid.
Extract/fractions Concentration (mg/ml) Log2 HA titer/50 ml
supernatant
24 ha 48 ha
Crude extract 100 0.5 ± 1 1.33 ± 1.5
31.6 2.25 ± 1.5 3.66 ± 1.15
10 3.5 ± 1.29 5.66 ± 1.15
3.1 4.75 ± 1.7 6 ± 2
virus control 5.25 ± 1.7 7 ± 1
Total alkaloid 31.6 0.25 ± 0.5 2.33 ± 0.58
10 2.25 ± 1.7 5 ± 2
3.6 3.5 ± 1.3 5 ± 1
1 4.5 ± 2.1 6.33 ± 1.53
virus control 5.25 ± 1.7 7 ± 1
Oseltamivir (mmol)b 5 0 0
2.5 0 0.5 ± 0.71
1.25 0 4
virus control 5 ± 1.4 8
a Hours post-infection.
b Oseltamivir was used as positive controls.
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ment (virus without extract).2.13. Western blot analysis
MDCK cells in 6-well plates were inoculated with PR8 at
(100TCID50) in the presence of crude extract (100 and 50 mg/ml) for
24 h at 37 C. The culture medium was removed and cells were
washed twice with cold PBS and lysed in ice-cold radio immune
precipitation assay buffer (6  ) containing protease inhibitor
cocktail. Protein concentration was measured by Bradford assay
(BioRad), and the equal amounts of protein from each sample were
subjected to blotting.
The protein lysates were mixed with SDS loading buffer
(0.125 M Tris-HCl 4%, SDS 20%, glycine 10%, and 2-mercapto-
ethanol), followed by boiling for 5 min and separated by 12% so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDSePAGE) and transferred to polyvinylidene diﬂuoride (PVDF;
Bio-Rad, USA) membrane using semi-dry transfer system (Bio-Rad,USA). Viral nucleoprotein (NP) and M1 protein, and cellular b-actin
protein (loading control) were detected with anti-NP (Thermo
Fisher Scientiﬁc, USA), anti-M1 (Thermo Fisher Scientiﬁc, USA) and
b-actin antibodies (Abcam; USA), respectively. The horseradish
peroxidase (HRP) conjugated secondary antibodies (goat anti-
rabbit/IgG) were used and the bound antibodies were detected
using C-DiGit® Blot Scanner (LI-COR, USA).
2.14. Statistical analysis
The data were statistically evaluated using a kruskal-wallis to
compare differences between the groups. A p-value of <0.05 was
considered to be signiﬁcant. The IC50 and CC50 values were calcu-
lated by regression analysis and related models with probit
regressionmodel procedure, using the SPSS software (version 16.0).
3. Results
3.1. Cytotoxicity and antiviral activity of the extracts and total
alkaloid
The results showed that the CC50 value of crude extract and total
alkaloide on MDCK cells were 122.9 (CI95%: 107.8e140) and 133.9
(CI95%: 121.9e147) mg/ml respectively. The analysis showed a sig-
niﬁcant relationship between the concentration of the extract/
alkaloid and cell death (the more the increase in the extract con-
centration was, the more the cell death was (P < 0.05; Fig. 1).
MDCK cells were inoculated with PR8 virus for 1 h. Then, the
virus was removed and the cells were treated with serial two fold
dilutions of nontoxic concentration of the extract or total alkaloid.
Our results showed that more the extract concentration, more the
CPE inhibition (Fig. 1, p < 0.05). Based on regression analysis, IC50 of
crud extract and total alkaloid inﬂuenza virus were 9.87 (CI95%:
7.3e11.3) and 5.8 (CI95%: 3.7e8.9) mg/ml with SI value of 12.45 and
23.1 respectively. In comparison, The IC50 and CC50 of oseltamivir
were 539.4 (CI95%: 378.9e768.5) and 0.873 (CI95%: 0.55e1.37)
mmol with SI value of 617.8.
Antiviral activity of the extract/alkaloid against inﬂuenza virus
was assessed by HA endpoint test. According to the results, the titer
of virus was reduced upon treatment with crude extract and total
alkaloid in a dose-dependent manner (Table 2).
Fig. 2. Decrease of inﬂuenza viral titers in the culture supernatants by the Peganum harmala L. seed crud extract and its total alkaloids. PR8-infected MDCK cells were
incubated with different concentrations of the extract/alkaloid for 24 h and the supernatants were used for TCID50 titration (A) or for viral RNA quantiﬁcation by quantitative RT-PCR
(B). Oseltamivir was used as positive controls (mmol). The data are the mean values of three independent experiments (mean ± SD). P values were calculated against virus control
(untreated sample) using Kruskal Wallis test,*P < 0.05.
Fig. 3. Time-of-addition activity of Peganum harmala L. seed extract on inﬂuenza virus. PR8 virus was absorbed to MDCK cells (104 TCID50) for 1 h at 4 C. After washing of non-
absorbed virus, the crude extract was added at its maximum nontoxic concentration (100 mg/ml) to the cell-virus system at the following time points: 2 to 1 h (before the
adsorption of the virus), 1 to 0 h (adsorption) as well as at several time points post adsorption: 0e2, 2e4, and 4e8 h. Virus titer was determined after 8 h of incubation in MDCK
cells using TCID50 assay.
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inhibitory effect on infectious virus yield, the virus was titrated by
HA endpoint test, TCID50 method and quantitative RT-PCR analyses.
The results showed that, crude extract and total alkaloid signiﬁ-
cantly reduced the levels of infectious viral titers and viral RNA
levels (Table 2 and Fig. 2).3.2. P. harmala L. seed extract inhibits late stages of inﬂuenza virus
infection
To determine the stage of viral cycle when the extractdemonstrates its activity, time-of-addition experiments were per-
formed. Evaluation of virus titer indicated that crude extract did not
interfere with virus absorption (1 to 0 h) or receptor binding (2
to 1) step. In addition, decrease in the virus titer was observed at
time points 4 to 8 and 2e4 h. Maximum virus inhibition by the
extract was seen at the time point 2 to 8 h post infection (Fig. 3).3.3. P. harmala seed extract inhibit viral protein synthesis
The levels of inﬂuenza viral mRNAwere compared between the
crude extract treated and untreated infected cells. RNA extraction
Fig. 4. Effects of Peganum harmala L. seed extract on the expression of viral mRNA in MDCK cells. Cells were infected with PR8 virus and treated with different concentrations
(100, 31.6 and 10 mg/mL) of the extract. Total RNA was extracted at 13 h after inﬂuenza virus infection and the levels of intracellular mRNA inﬂuenza genes (NS1, NP, M1, and HA)
were measured. Inﬂuenza viral mRNA levels normalized to GAPDH. The data are the mean values of 2 independent repeats in duplicate (mean ± SD). P values were calculated
against virus control (untreated sample) using Kruskal Wallis test.
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of intracellular inﬂuenza virus mRNA (NS1, NP, HA and M2 genes)
were measured. Quantitative real-time PCR showed a signiﬁcant
decrease in inﬂuenza mRNA expression level from the crude ex-
tracts treated cells dose-dependently compared with untreated
virus infected cells (P < 0.05; Fig. 4).
In order to detect viral protein synthesis in the cells following
the inoculation of the virus, viral NP and M1 were studied using
western blot analysis. We found that the extract inhibits the viral
protein synthesis in a dose-dependent manner (Fig. 5). These re-
sults indicate that the P. harmala extract have inhibitory effects on
the viral protein synthesis.3.4. P. harmala extract inhibit viral RNA replication
The synthesis of viral RNA in MDCK cells were compared be-
tween various concentration of crud extract treated or untreated
was analyzed at 13 h after the inoculation of the virus.
The extract effects on viral RNA load levels were shown by log10
copy number decrements in treatments which were calculated
through absolute quantiﬁcation. Quantitative analysis on the M2
gene of inﬂuenza virus showed statistically signiﬁcant decrements
in viral load compared to the virus sample in a dose-dependent
manner (Table 3).
Fig. 5. Effects of Peganum harmala L. seed extract on the protein synthesis in
MDCK cells. MDCK cells were infected with PR8 virus and then incubated with
different concentrations (100 and 50 mg/ml) of the extract for 24 h at 37 C. The viral
proteins, NP and M1, were detected using their speciﬁc primary antibodies and HRP-
conjugated secondary antibodies. Cellular b-actin was used as a loading control. Well
1: virus control, well 2: virus þ50 mg/mL crude extract, well 3: virus þ100 mg/mL
crude extract.
Table 3
Effects of Peganum harmala L. seed extract on the viral RNA copy number.
Concentration (mg/ml) Ct (Mean ± SD) Log10 copy numbers (Mean ± SD)
100 28.76 ± 0.89 1.88 ± 0.225*
31.6 25.18 ± 1.16 2.78 ± 0.29
10 23.9 ± 1.25 3.10 ± 0.315
Virus control (untreated) 17.59 ± 0.41 4.69 ± 0.10
Cells were infected with PR8 virus and treated with different concentrations (100,
31.6 and 10 mg/ml) of crude extract. Total RNA was extracted at 13 h after inﬂuenza
virus infection and the Log10 copy numbers relating to Ct values of intracellular
inﬂuenza M gene were measured. Data were averages of 2 independent repeats in
duplicate. *(p < 0.05) comparison with the virus untreated sample using Kruskal
Wallis test.
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P. harmala seed extract
To elucidate the mechanism of antiviral activity of the extract,
another series of experiments was conducted Study of virucidal
activity showed that virus yield in the extract and control was
5.5 ± 0.56 and 5.08 ± 0.59 (log 10-TCID50) respectively (p > 0.05).
This conﬁrms that the extract has no virucidal activity and this
mechanism should not be considered for the extract.
To determine whether the crud extract can prevent the ability of
virus particles to bind to cell surface receptors, we used HI assays.
The HA assay results indicated that pretreatment with the crude
extract could not prevent the binding of virus to RBCs (data not
shown).
4. Discussion
P. harmala seed has been considered from long time ago as a
herbal medicine. It has been reported that P. harmala have anti-
microbial [38], antiviral [39,40], and antiplasmodial [19] activities.
To the best of our knowledge, to date, there has been no report on
the anti-inﬂuenza virus activity of P. harmala seed extract. There-
fore, in this study anti-inﬂuenza virus activity of P. harmala seed
extract was evaluated through inhibiting the viral RNA transcrip-
tion and replication in MDCK cell line.
In the present study, the crude extract inhibited inﬂuenza A PR8
virus replication in this cell line, with IC50 value of about 9.87
(CI95%: 7.3e11.3)mg/ml and SI value of 12.45. Using additional
antiviral assays, which measured the titers of HA or infectious viral
particles in the culture supernatants, as well as the viral RNA and
viral protein levels in the cell lysates, it was ensured that the crude
extract of P. harmala seed could suppress production of infectious
inﬂuenza viruses. As an IC50 value of a characteristic herbal extract
against infectious diseases is less than 100 mg/mL [41], this extractwith IC50 of 9.87 should have strong activity against inﬂuenza virus.
Our results showed that the total alkaloids of this extract had
antiviral activity, with IC50 value of about 5.8 (CI95%: 3.7e8.9)mg/ml
and SI value of 23.1, better than that of the crude extract. Other
studies showed that pharmacologically active compounds of
P. harmala include several alkaloids, b-carbolines (such as harmine,
harmaline, harman and harmalol) and the quinazoline derivatives
of vasicine and vasicinone [16]. It has been reported that some of
the b-carboline alkaloids also have antiviral [39,40], activities. It has
been also shown that alkaloid compounds of the b-carbolines [42]
and the quinazoline [43,44] have anti-inﬂuenza A virus activity.
Therefore, the anti-inﬂuenza A virus activity of the P. harmala seed
extract used in this study could be attributed to its b-carboline
alkaloids.
In this study, using quantitative real-time PCR, western blot
analysis, and time course study, the effect of P. harmal extract on
inﬂuenza virus replication in MDCK cell line was investigated.
Based on our study, the effect of extract on reduction of the RNA
level and the viral polymerase activity was evident. In inﬂuenza
virus particle, the genomic RNAs (vRNAs) are associated with
multiple copies of nucleoproteins (NPs) and a small number of
RNA-dependent RNA polymerase complexes, that consist PA, PB1,
and PB2, which together form the ribonucleoprotein complex
(RNP) which is essential for the transcription and replication of the
viral RNAs [45]. Based our results, P. harmala seed extract may
decrease the level of NP and viral polymerase activity, and thus
affects the RNP complexes' activity, leading to inhibition of both
viral RNA transcription and replication.
Time course study of one cycle of inﬂuenza virus replication
showed that the extract inhibited the inﬂuenza replication but did
not interfere with virus absorption or receptor binding step. The
recent claim was supported by HI assay that the attendance of the
extract was not show any inhibitory effect on virus-induced HA.
The maximal virus inhibition was achieved at time points 4e8 and
2e4 h post infection during late stages of the viral replication cycle.
This stage include the synthesis of inﬂuenza virus late proteins and
their subsequent assembly into functionally active complex.
Further studies are needed to identify the precise target of this
extract on the inﬂuenza virus life cycle.
This study showed that, in vitro antiviral activity of P. harmala
seed extract against inﬂuenza virus is most probably associated
with inhibiting viral RNA transcription. Therefore, this extract and
its total alkaloid should be further characterized to be developed as
anti-inﬂuenza A virus agent.
Author contributions
All the authors have accepted responsibility for the entire con-
tent of this submitted manuscript and approved submission.
Research funding
Deputy of Research and Technology of Shahrekord University of
Medical Sciences, Shahrekord, Iran.
Competing interests
The funding organization(s) played no role in the study design;
in the collection, analysis, and interpretation of data; in the writing
of the report; or in the decision to submit the report for publication.
Acknowledgments
This work was supported by the Shahrekord University of
Medical Science, Shahrekord, Iran (Grant No.:1945). Authors are
M.-T. Moradi et al. / Microbial Pathogenesis 110 (2017) 42e49 49thankful to the Director of Medical Plants Research Center and to
the Deputy of Research and Technology of Shahrekord University of
Medical Sciences, Shahrekord, Iran.
References
[1] w.h.o (WHO), Inﬂuenza (Seasonal), Fact Sheet, world health organization
(WHO), 2016, http://www.who.int/mediacentre/factsheets/fs211/en/
(Accessed 13 March 2017).
[2] F.S. Dawood, S. Jain, L. Finelli, M.W. Shaw, S. Lindstrom, R.J. Garten, et al.,
Emergence of a novel swine-origin inﬂuenza A (H1N1) virus in humans,
N. Engl. J. Med. 360 (25) (2009) 2605e2615.
[3] J.J. Cannell, M. Zasloff, C.F. Garland, R. Scragg, E. Giovannucci, On the epide-
miology of inﬂuenza, Virol. J. 5 (29) (2008), 422X-5.
[4] F.G. Hayden, Respiratory viral threats, Curr. Opin. Infect. Dis. 19 (2) (2006)
169e178.
[5] R.J. Jackson, K.L. Cooper, P. Tappenden, A. Rees, E.L. Simpson, R.C. Read, et al.,
Oseltamivir, zanamivir and amantadine in the prevention of inﬂuenza: a
systematic review, J. Infect. 62 (1) (2011) 14e25.
[6] E. van der Vries, M. Schutten, P. Fraaij, C. Boucher, A. Osterhaus, Inﬂuenza
virus resistance to antiviral therapy, Adv. Pharmacol. 67( (2013) 217e246.
[7] C. Dapat, H. Kondo, I.C. Dapat, T. Baranovich, Y. Suzuki, Y. Shobugawa, et al.,
Neuraminidase inhibitor susceptibility proﬁle of pandemic and seasonal
inﬂuenza viruses during the 2009-2010 and 2010-2011 inﬂuenza seasons in
Japan, Antivir. Res. 99 (3) (2013) 261e269.
[8] F. Hayden, Developing new antiviral agents for inﬂuenza treatment: what
does the future hold? Clin. Infect. Dis. 48 (Suppl 1) (2009) S3eS13.
[9] T. Jefferson, C. Di Pietrantonj, M.G. Debalini, A. Rivetti, V. Demicheli, Inacti-
vated inﬂuenza vaccines: methods, policies, and politics, J. Clin. Epidemiol. 62
(7) (2009) 677e686.
[10] A. Lackenby, C.I. Thompson, J. Democratis, The potential impact of neur-
aminidase inhibitor resistant inﬂuenza, Curr. Opin. Infect. Dis. 21 (6) (2008)
626e638.
[11] A. Karimi, M.T. Moradi, S. Alidadi, L. Hashemi, Anti-adenovirus activity, anti-
oxidant potential, and phenolic content of black tea (Camellia sinensis Kuntze)
extract, J. Complement. Integr. Med. 13 (4) (2016) 357e363.
[12] A. Karimi, M. Raﬁeian-Kopaei, M.T. Moradi, S. Alidadi, Anti-Herpes simplex
virus Type-1 activity and phenolic content of crude ethanol extract and four
corresponding fractions of Quercus brantii L Acorn, J. Evid. Based. Comple-
ment. Altern. Med. 22 (3) (2017) 455e461.
[13] M.T. Moradi, M. Raﬁeian-Kopaei, A. Karimi, A review study on the effect of
Iranian herbal medicines against in vitro replication of herpes simplex virus,
Avicenna J. Phytomed 6 (5) (2016) 506e515.
[14] M. Mahmoudian, H. Jalipour, P. Salehian Dardashti, Toxicity of Peganum har-
mala: review and a case report, Iran. J. Pharm. Ther. 1 (1) (2002) 1e4.
[15] T. Zhao, Z.T. Wang, C.J. Branford-White, H. Xu, C.H. Wang, Classiﬁcation and
differentiation of the genus Peganum indigenous to China based on chloro-
plast trnL-F and psbA-trnH sequences and seed coat morphology, Plant Biol.
(Stuttg) 13 (6) (2011) 940e947.
[16] C.N. Mina, M.H. Farzaei, A. Gholamreza, Medicinal properties of Peganum
harmala L. in traditional Iranian medicine and modern phytotherapy: a re-
view, J. Tradit. Chin. Med. 35 (1) (2015) 104e109.
[17] M. Moloudizargari, P. Mikaili, S. Aghajanshakeri, M.H. Asghari, J. Shayegh,
Pharmacological and therapeutic effects of Peganum harmala and its main
alkaloids, Pharmacogn. Rev. 7 (14) (2013) 199e212.
[18] N. Bukhari, J. Choi, C. Jeon, H. Park, W. Kim, M.A. Khan, et al., Phytochemical
studies of the alkaloids from Peganum harmala, Appl. Cham 12 (1) (2008)
101e104.
[19] A. Astulla, K. Zaima, Y. Matsuno, Y. Hirasawa, W. Ekasari, A. Widyawaruyanti,
et al., Alkaloids from the seeds of Peganum harmala showing antiplasmodial
and vasorelaxant activities, J. Nat. Med. 62 (4) (2008) 470e472.
[20] P. Sathiyamoorthy, H. Lugasi-Evgi, P. Schlesinger, I. Kedar, J. Gopas, Y. Pollack,
et al., Screening for cytotoxic and Antimalarial activities in desert plants of the
negev and bedouin market plant products, Pharm. Biol. 37 (3) (1999)
188e195.
[21] G. Nenaah, Antibacterial and antifungal activities of (beta)-carboline alkaloids
of Peganum harmala (L) seeds and their combination effects, Fitoterapia 81 (7)
(2010) 779e782.
[22] K. Rharrabe, A. Bakrim, N. Ghailani, F. Sayah, Bioinsecticidal effect of harma-
line on plodia interpunctella development (Lepidoptera: Pyralidae), Pestic.Biochem. Physiol. 89 (2) (2007) 137e145.
[23] R. Jbilou, H. Amri, N. Bouayad, N. Ghailani, A. Ennabili, F. Sayah, Insecticidal
effects of extracts of seven plant species on larval development, alpha-
amylase activity and offspring production of Tribolium castaneum (Herbst)
(Insecta: Coleoptera: Tenebrionidae), Bioresour. Technol. 99 (5) (2008)
959e964.
[24] J. Asgarpanah, F. Ramezanloo, Chemistry, pharmacology and medicinal
properties of Peganum harmala L, Afr. J. Pharm. Pharmacol. 6 (22) (2012)
1573e1580.
[25] S. Kiani, M. Shamsi Shahrabadi, A. Ataei, N. Sajjadi, Peganum harmala seed
extract can prevent HSV-1 replication in vitro, Iran. J. Virol. 4( (2008) 11e16.
[26] W.P. Jones, D. Kinghorn, Extractio of plant secondary metabolites, in:
S.D. Sarker, Z. Latif, L.I. Gray (Eds.), Natural Products Isolation, second ed.,
Humane press, Totowa, New jersey, 2006, pp. 323e353.
[27] T. Mosmann, Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays, J. Immunol. Methods 65
(1e2) (1983) 55e63.
[28] Y.J. Jang, R. Achary, H.W. Lee, H.J. Lee, C.K. Lee, S.B. Han, et al., Synthesis and
anti-inﬂuenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyr-
idin-3(1H)-ones, Antivir. Res. 107( (2014) 66e75.
[29] Y. Kim, S. Narayanan, K.O. Chang, Inhibition of inﬂuenza virus replication by
plant-derived isoquercetin, Antivir. Res. 88 (2) (2010) 227e235.
[30] WHO, Manual for the Laboratory Diagnosis and Virological Surveillance of
Inﬂuenza. Global Inﬂuenza Surveillance and Response System (GISRS). http://
www.who.int/inﬂuenza/gisrs_laboratory/manual_diagnosis_surveillance_
inﬂuenza/en/. (Accessed 20 March 2016).
[31] L.J. Reed, H. Muench, A simple method of estimating ﬁfty per cent endpoints,
Am. J. Epidemiol. 27 (3) (1938) 493e497.
[32] O.V. Matusevich, V.V. Egorov, I.A. Gluzdikov, M.I. Titov, V.V. Zarubaev,
A.A. Shtro, et al., Synthesis and antiviral activity of PB1 component of the
inﬂuenza A RNA polymerase peptide fragments, Antivir. Res. 113( (2015)
4e10.
[33] V.V. Zarubaev, A.V. Garshinina, T.S. Tretiak, V.A. Fedorova, A.A. Shtro,
A.S. Sokolova, et al., Broad range of inhibiting action of novel camphor-based
compound with anti-hemagglutinin activity against inﬂuenza viruses in vitro
and in vivo, Antivir. Res. 120( (2015) 126e133.
[34] W. He, H. Han, W. Wang, B. Gao, Anti-inﬂuenza virus effect of aqueous ex-
tracts from dandelion, Virol. J. 8 (2011) 538.
[35] K. Yamada, H. Ogawa, A. Hara, Y. Yoshida, Y. Yonezawa, K. Karibe, et al.,
Mechanism of the antiviral effect of hydroxytyrosol on inﬂuenza virus appears
to involve morphological change of the virus, Antivir. Res. 83 (1) (2009)
35e44.
[36] C. Godornes, B.T. Leader, B.J. Molini, A. Centurion-Lara, S.A. Lukehart, Quan-
titation of rabbit cytokine mRNA by real-time RT-PCR, Cytokine 38 (1) (2007)
1e7.
[37] A. Abdal Dayem, H.Y. Choi, Y.B. Kim, S.G. Cho, Antiviral effect of methylated
ﬂavonol isorhamnetin against inﬂuenza, PLoS One 10 (3) (2015) e0121610.
[38] A.R. Shahverdi, S.N. Ostad, S. Khodaee, L. Bitarafan, H.R. Monsef-Esfahani,
H. Jamalifar, et al., PHCOG MAG.: research article antimicrobial and cytotox-
icity potential of Peganum harmala smoke, Phcog. Mag. 4 (15) (2008) 236.
[39] J. Ishida, H.K. Wang, M. Oyama, M.L. Cosentino, C.Q. Hu, K.H. Lee, Anti-AIDS
agents. 46. anti-HIV activity of harman, an anti-HIV principle from symplocos
setchuensis, and its derivatives, J. Nat. Prod. 64 (7) (2001) 958e960.
[40] J.B. Hudson, E.A. Graham, R. Fong, L.L. Hudson, G.H. Towers, Further studies on
the antiviral activity of harmine, a photoactive beta-carboline alkaloid, Pho-
tochem. Photobiol. 44 (4) (1986) 483e487.
[41] P. Cos, A.J. Vlietinck, D.V. Berghe, L. Maes, Anti-infective potential of natural
products: how to develop a stronger in vitro ‘proof-of-concept’,
J. Ethnopharmacol. 106 (3) (2006) 290e302.
[42] G. Zhang, B. Zhang, X. Zhang, F. Bing, Homonojirimycin, an alkaloid from
dayﬂower inhibits the growth of inﬂuenza A virus in vitro, Acta Virol. 57 (1)
(2013) 85e86.
[43] Z. Dang, K. Jung, L. Zhu, W. Lai, H. Xie, K.-H. Lee, et al., Identiﬁcation and
synthesis of quinolizidines with anti-inﬂuenza A virus activity, ACS Med.-
Chem. Lett. 5 (8) (2014) 942e946.
[44] Q.M. Pan, Y.H. Li, J. Hua, F.P. Huang, H.S. Wang, D. Liang, Antiviral matrine-
type alkaloids from the rhizomes of Sophora tonkinensis, J. Nat. Prod. 78 (7)
(2015) 1683e1688.
[45] Y. Sugita, H. Sagara, T. Noda, Y. Kawaoka, Conﬁguration of viral ribonucleo-
protein complexes within the inﬂuenza A virion, J. Virol. 87 (23) (2013)
12879e12884.
